Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
05/02/2024 | Press release | Distributed by Public on 05/02/2024 17:11
Please select the service you want to use:
Smartlinks | Till Capital Corporation | Company News | Top Company News | Business Announcement | Financial Services | Insurance | Securities Issuers | Reinsurance Companies | OTC Markets | TSX Venture Exchange | Cboe Canada | Omega ATS | Lynx ATS | CSE Pure Trading | Nasdaq CX2 | Nasdaq CXC | TSX Alpha Exchange
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact